An­ti­sense start­up Stoke Ther­a­peu­tics se­cures an­oth­er $90M in se­ries B fund­ing

Led by for­mer Sarep­ta CEO, an­ti­sense start­up Stoke Ther­a­peu­tics has raked in $90 mil­lion in se­ries B fi­nanc­ing, fol­low­ing up the $40 mil­lion an­nounced ear­li­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER